Immediate Impact
2 by Nobel laureates 2 from Science/Nature 61 standout
Citing Papers
Immune checkpoint therapy—current perspectives and future directions
2023 StandoutNobel
Targeting hypoxia-inducible factors: therapeutic opportunities and challenges
2023 Standout
Works of Motti Farbstein being referenced
A phase II, randomized, double-blind, placebo-controlled trial evaluating efficacy and safety of namodenoson (CF102), an A3 adenosine receptor agonist (A3AR), as a second-line treatment in patients with Child-Pugh B (CPB) advanced hepatocellular carcinoma (HCC).
2019
CF102 for the Treatment of Hepatocellular Carcinoma: A Phase I/II, Open-Label, Dose-Escalation Study
2012
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Motti Farbstein | 41 | 104 | 13 | 67 | 7 | 183 | |
| Jonathan Matalonga | 39 | 20 | 3 | 74 | 7 | 214 | |
| Xianqiu Zeng | 9 | 59 | 4 | 133 | 6 | 293 | |
| Suzanne A. B. M. Aarts | 56 | 36 | 4 | 65 | 8 | 245 | |
| Jair Machado Espindola Netto | 44 | 94 | 4 | 64 | 4 | 283 | |
| Charles Kiehlbauch | 70 | 26 | 9 | 150 | 9 | 272 | |
| Katarzyna Parzych | 34 | 25 | 5 | 133 | 7 | 227 | |
| Timna Varela Martins | 34 | 12 | 5 | 110 | 9 | 243 | |
| Xueying Wang | 26 | 29 | 1 | 156 | 11 | 253 | |
| Melinde Wijers | 31 | 15 | 4 | 94 | 7 | 245 | |
| Ilan Cohn | 18 | 126 | 6 | 71 | 4 | 163 |
All Works
Loading papers...